A5011528218- Glioma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Virus-based gene therapy research
- CAR-T cell therapy research
- Meningioma and schwannoma management
- Neutropenia and Cancer Infections
- Bone and Joint Diseases
- Vascular Malformations and Hemangiomas
- Radiomics and Machine Learning in Medical Imaging
- Chromatin Remodeling and Cancer
- Vascular Tumors and Angiosarcomas
- Immunotherapy and Immune Responses
- Hematological disorders and diagnostics
- Cancer Research and Treatments
- Ocular Oncology and Treatments
- Ear and Head Tumors
- ATP Synthase and ATPases Research
- Melanoma and MAPK Pathways
- Cancer therapeutics and mechanisms
University of Alabama at Birmingham
2023-2024
Children's of Alabama
2022-2024
NYU Langone Health
2024
New York University Langone Orthopedic Hospital
2020
The University of Texas MD Anderson Cancer Center
2018-2019
Viroimmunotherapy is evolving as a strong alternative for the standard treatment of malignant gliomas. Promising results from recent clinical trial testing anticancer effect Delta-24-RGD in patients with glioblastoma suggested induction antitumoral immunity after viral administration. To further enhance anti-glioma immune effect, we have armed costimulatory ligand GITRL (Delta-24-GREAT [Glucocorticoid Receptor Enhanced Activity T cells]).We tested infectivity and replication Delta-24-GREAT,...
Abstract Background There is no standard treatment for the recurrence of medulloblastoma, most common malignant childhood brain tumor, and prognosis remains dismal. In this study, we introduce a regimen that well-tolerated effective at inducing remission. Methods The primary objectives study were to assess tolerability overall response rate (ORR). A retrospective chart review patients with recurrent treated two institutions re-induction intravenous irinotecan cyclophosphamide oral...
Abstract INTRODUCTION Vascular endothelial growth factor receptor (VEGFR), platelet derived (PDGFR), and c-KIT represent clinically and/or preclinically validated molecular targets in vestibular schwannomas. We conducted a single institution, prospective, open-label, two-stage phase II study (ClinicalTrials.gov identifier NCT02129647) to estimate the response rate axitinib, an oral multi-receptor tyrosine kinase inhibitor targeting VEGFR, PDGFR c-KIT, neurofibromatosis type 2 (NF2) patients...
Abstract BACKGROUND Axitinib is an oral multi-receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet derived (PDGFR), and c-KIT. These represent a clinically and/or preclinically validated molecular targets in vestibular schwannoma (VS). METHODS Eligible participants were age >5 years with clinical diagnosis of neurofibromatosis type 2-related schwannomatosis (NF2-SWN) at least one volumetrically measurable, progressive VS. was given...
Ganglioglioma (GG) is a rare mixed glioneuronal neoplasm accounting for 0.5–5% of all pediatric central nervous system tumors. BRAF V600E mutation has been previously reported in GG but its incidence and impact remain unknown. This retrospective study evaluates the prognostic implication. PATIENTS AND Retrospective review 55 patients under age 21 years diagnosed with at our institution from 1992 to 2012 was performed. Patient demographics, clinical history, radiological features, treatment...
Abstract Based on promising results of recent clinical trials using oncolytic viruses, virotherapy is evolving as an alternative to treat patients with malignant glioma. Our group developed the adenovirus Delta-24-RGD (DNX-2401) that being tested, alone or in combination anti-PD1, for recurrent glioblastoma (NCT00805376; NCT01956734; NCT02798406). The suggest that, besides expected effect, injection pathogen initiated, a subset patients, anti-tumoral immunity led 20% long-term survivors...
Abstract Medulloblastoma is the most common malignant brain tumor of childhood. Despite multi-modal therapies, ~30% patients experience disease recurrence, which portends a poor prognosis. At initial intensive chemotherapy may be effective prior to various consolidation therapies including high dose with autologous stem cell rescue or irradiation. We report outcomes for nine children treated at two institutions following regimen: cyclophosphamide 1500mg/m2/dose days 1,2; irinotecan...
Embryonal Tumor with Multilayered Rosettes (ETMR) is a rare tumor of the central nervous system (CNS) poor prognosis. To date no defined robust treatment strategy or advanced brain imaging (ABTI) have been described for these malignancies. We performed retrospective analysis and identified 8 pathology-proven ETMR cases from 2010–2017 treated at our institution, evaluated institutional experience, including characteristics. Age ranged 1.11 to 12.8 years. Tumors were located in brainstem,...